Clearpoint Historical Financial Ratios
| CLPT Stock | USD 16.43 0.25 1.50% |
Clearpoint Neuro is presently reporting on over 99 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 8.29 or Days Sales Outstanding of 42.97 will help investors to properly organize and evaluate Clearpoint Neuro financial condition quickly.
Clearpoint |
About Clearpoint Financial Ratios Analysis
Clearpoint NeuroFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Clearpoint Neuro investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Clearpoint financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Clearpoint Neuro history.
Clearpoint Neuro Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Clearpoint Neuro stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Clearpoint Neuro sales, a figure that is much harder to manipulate than other Clearpoint Neuro multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Research And Ddevelopement To Revenue
The ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services.Revenue Per Share
The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.Most ratios from Clearpoint Neuro's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Clearpoint Neuro current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.At this time, Clearpoint Neuro's Research And Ddevelopement To Revenue is comparatively stable compared to the past year. Capex To Revenue is likely to gain to 0.05 in 2024, whereas Operating Cash Flow Per Share is likely to drop (0.59) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 11.73 | 25.81 | 26.31 | 27.63 | Days Of Inventory On Hand | 359.9 | 483.7 | 279.23 | 407.41 |
Clearpoint Neuro fundamentals Correlations
Click cells to compare fundamentals
Clearpoint Neuro Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Clearpoint Neuro fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 5.63 | 19.63 | 14.27 | 9.97 | 6.97 | 7.13 | |
| Ptb Ratio | 13.77 | 105.95 | 4.77 | 5.55 | 7.89 | 8.29 | |
| Days Sales Outstanding | 35.47 | 53.52 | 52.33 | 47.33 | 60.09 | 42.97 | |
| Book Value Per Share | 0.35 | 0.15 | 2.35 | 1.53 | 0.86 | 0.9 | |
| Free Cash Flow Yield | (0.0477) | (0.0329) | (0.0553) | (0.0845) | (0.0884) | (0.0928) | |
| Operating Cash Flow Per Share | (0.22) | (0.49) | (0.61) | (0.67) | (0.56) | (0.59) | |
| Stock Based Compensation To Revenue | 0.0712 | 0.085 | 0.13 | 0.2 | 0.25 | 0.23 | |
| Capex To Depreciation | 0.64 | 0.87 | 0.24 | 1.47 | 0.72 | 0.39 | |
| Pb Ratio | 13.77 | 105.95 | 4.77 | 5.55 | 7.89 | 8.29 | |
| Ev To Sales | 5.34 | 19.95 | 11.71 | 9.21 | 6.59 | 10.2 | |
| Free Cash Flow Per Share | (0.23) | (0.52) | (0.62) | (0.72) | (0.6) | (0.63) | |
| Roic | (1.06) | (0.81) | (0.35) | (0.24) | (0.71) | (0.75) | |
| Inventory Turnover | 1.18 | 1.15 | 1.01 | 0.75 | 1.31 | 0.84 | |
| Net Income Per Share | (0.49) | (0.57) | (0.74) | (0.68) | (0.9) | (0.94) | |
| Days Of Inventory On Hand | 308.56 | 318.65 | 359.9 | 483.7 | 279.23 | 407.41 | |
| Payables Turnover | 3.97 | 12.36 | 11.73 | 25.81 | 26.31 | 27.63 | |
| Sales General And Administrative To Revenue | 0.38 | 0.41 | 0.54 | 0.47 | 0.49 | 0.57 | |
| Research And Ddevelopement To Revenue | 0.26 | 0.37 | 0.55 | 0.53 | 0.49 | 0.7 | |
| Capex To Revenue | 0.0143 | 0.0376 | 0.0103 | 0.0558 | 0.0439 | 0.0461 | |
| Cash Per Share | 0.43 | 1.27 | 2.61 | 1.55 | 0.94 | 0.89 | |
| Pocfratio | (22.16) | (32.26) | (18.32) | (12.67) | (12.18) | (12.79) | |
| Interest Coverage | (4.81) | (4.31) | (13.75) | (201.63) | (231.87) | (220.28) | |
| Capex To Operating Cash Flow | (0.0562) | (0.0617) | (0.0132) | (0.0709) | (0.0766) | (0.0728) | |
| Pfcf Ratio | (20.98) | (30.38) | (18.08) | (11.83) | (11.31) | (11.88) | |
| Days Payables Outstanding | 91.99 | 29.52 | 31.12 | 14.14 | 13.87 | 13.18 | |
| Roe | (1.42) | (3.83) | (0.31) | (0.45) | (1.04) | (0.99) | |
| Ev To Operating Cash Flow | (21.03) | (32.79) | (15.03) | (11.7) | (11.51) | (12.08) | |
| Pe Ratio | (9.71) | (27.65) | (15.19) | (12.38) | (7.56) | (7.94) | |
| Return On Tangible Assets | (0.55) | (0.31) | (0.23) | (0.3) | (0.53) | (0.56) | |
| Ev To Free Cash Flow | (19.91) | (30.88) | (14.83) | (10.93) | (10.69) | (11.22) | |
| Earnings Yield | (0.1) | (0.0362) | (0.0659) | (0.0807) | (0.13) | (0.14) | |
| Net Debt To E B I T D A | 0.75 | (0.87) | 3.28 | 1.0 | 0.44 | 0.46 | |
| Current Ratio | 2.58 | 7.87 | 13.02 | 7.54 | 4.87 | 3.02 | |
| Tangible Book Value Per Share | 0.35 | 0.13 | 2.34 | 1.48 | 0.82 | 0.86 | |
| Receivables Turnover | 10.29 | 6.82 | 6.97 | 7.71 | 6.07 | 8.1 | |
| Graham Number | 1.32 | 1.97 | 1.39 | 6.25 | 4.84 | 4.17 | |
| Shareholders Equity Per Share | 0.35 | 0.15 | 2.35 | 1.53 | 0.86 | 0.9 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.